Echinocandins represent the first-line therapy of candidemia. Echinocandin resistance among Candida spp. is mainly due to acquired FKS mutations. In this study, we report the emergence of FKS-mutant Candida albicans/glabrata in Switzerland and provide the microbiological and clinical characteristics of 9 candidemic episodes. All patients were previously exposed to echinocandins (median 26 days; range 15–77). Five patients received initial echinocandin therapy with persistent candidemia in 4 of them. Overall mortality was 33%.
Mendeley helps you to discover research relevant for your work.
CITATION STYLE
Coste, A. T., Kritikos, A., Li, J., Khanna, N., Goldenberger, D., Garzoni, C., … Lamoth, F. (2020). Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland. Infection, 48(5), 761–766. https://doi.org/10.1007/s15010-020-01475-8